Method of isolating cd8+ cells, and related hybridoma cells, antibodies and polypeptides
CA 2365639 C · Owner: Ortho-Mcneil Pharmaceutical, Inc. · Inventors: Leturcq, Didier
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides a method of isolating CD8+ cells which employs an antibody which specifically binds to CD8 molecules present on the surface of CD8+ cells but does not activate the CD8+ cells once bound. This invention also provides related hybridoma cell lines monoclonal antibodies, antigenic , polypeptides isolated CD8+ cells, and kits.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 8, 2000 and granted May 14, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 8, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 8, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.